Compounds as HIF-1α inhibitors and manufacturing process thereof

A method of treating colon cancer in a subject in need thereof, comprising administering an effective amount of a pharmaceutical composition comprising a compound selected from the group consisting of:

• 2-(4-(Adamantan-1-yl)phenoxy)-1-(4-methylpiperazin-1-yl)ethanone (“I-3”);
• 2-(4-(Adamantan-1-yl)-2-methylphenoxy)-1-morpholinoethanone (“I-6”);
• 3-(4-(Adamantan-1-yl)phenoxy)-1-(4-methylpiperazin-1-yl)propan-1-one (“I-8”);
• 4-(2-(4-(Adamantan-1-yl)-2-methylphenoxy)acetyl)-1,1-dimethylpiperazin-1-ium iodide (“I-16”);
• 4-(4-(4-(Adamantan-1-yl)phenoxy)butanoyl)-1,1-dimethylpiperazin-1-ium iodide (“I-22”);
• and
• 2-(4-(Adamantan-1-yl)phenoxy)-2-methyl-1-(4-methylpiperazin-1-yl)propan-1-one (“I-23”),
• or a pharmaceutically acceptable base or acid addition salt, hydrate, or solvate thereof.